Our product candidates are designed to selectively modulate a class of molecular targets, called neuronal nicotinic receptors (NNRs), that are involved in regulating central nervous system activity. Multiple studies with nicotine and other compounds that interact with NNRs have validated NNRs as therapeutic targets. Our product candidates are designed to interact selectively with particular NNRs to promote therapeutic effects and limit adverse side effects.